title: Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model.
abstract: The aim of this study was to examine the anti-proliferative and anti-inflammatory effects of ezetimibe/simvastatin (E/S) after drug-eluting stent (DES) implantation in a porcine coronary restenosis model. Pigs were randomized into two groups in which the coronary arteries (23 pigs) had DES. Stents were deployed with oversizing (stent/artery ratio 1.3:1) in porcine coronary arteries. Fifteen pigs were taken 10/20 mg of E/S and eight pigs were not taken E/S. Histopathologic analysis was assessed at 28 days after stenting. In neointima, most inflammatory cells were lymphohistiocytes. Lymphohistiocyte count was not different between two groups (337+/-227 vs. 443+/-366 cells, P=0.292), but neointima area was significantly smaller (1.00+/-0.49 mm(2) vs. 1.69+/-0.98 mm(2), P=0.021) and percent area stenosis was significantly lower (23.3+/-10% vs. 39+/-19%, P=0.007) in E/S group compared with control group. There were no significant differences in fibrin score (1.99+/-0.79 vs. 1.81+/-0.88, P=0.49), endothelial score (1.75+/-0.66 vs. 1.80+/-0.59, P=0.79), and the percent of endothelium covered lumen (43+/-21% vs. 45+/-21%, P=0.84) between E/S group and control group. Combined therapy with ezetimibe and simvastatin inhibits neointimal hyperplasia, but does not inhibit inflammatory infiltration and arterial healing after DES implantation in a porcine coronary restenosis model.
authors.affiliation: Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.
authors.forename: Jung Sun
authors.initials: JS
authors.lastname: Cho
authors.forename: Myung Ho
authors.initials: MH
authors.lastname: Jeong
authors.forename: Doo Sun
authors.initials: DS
authors.lastname: Sim
authors.forename: Young Joon
authors.initials: YJ
authors.lastname: Hong
authors.forename: Kyung Seob
authors.initials: KS
authors.lastname: Lim
authors.forename: Jung Ha
authors.initials: JH
authors.lastname: Kim
authors.forename: Hyoung Doo
authors.initials: HD
authors.lastname: Kim
authors.forename: Ju Yeal
authors.initials: JY
authors.lastname: Baek
authors.forename: Hee Jeoung
authors.initials: HJ
authors.lastname: Yoon
authors.forename: Sung-Ho
authors.initials: SH
authors.lastname: Her
authors.forename: Seung Won
authors.initials: SW
authors.lastname: Jin
authors.forename: Ju Han
authors.initials: JH
authors.lastname: Kim
authors.forename: Youngkeun
authors.initials: Y
authors.lastname: Ahn
authors.forename: Jeong Gwan
authors.initials: JG
authors.lastname: Cho
authors.forename: Jong Chun
authors.initials: JC
authors.lastname: Park
authors.forename: Jung Chaee
authors.initials: JC
authors.lastname: Kang
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D001384:Azetidines / Q000008:administration & dosage*; D023903:Coronary Restenosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D004195:Disease Models, Animal; D004338:Drug Combinations; D004343:Drug Implants / Q000008:administration & dosage; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D000069438:Ezetimibe; D005260:Female; D006083:Graft Occlusion, Vascular / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D019821:Simvastatin / Q000008:administration & dosage*; D013552:Swine; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D004338:Drug Combinations; D004343:Drug Implants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin; D000069438:Ezetimibe